The VAS scores are reported to indicate severity of
subjective symptomatic pain in patients with chronic conditions
like OA, whereas WOMAC is mainly for functional
assessment of pain. In the present study, NR-INF-02
treatment significantly reduced both VAS and WOMAC
scores in comparison with placebo thus supporting its dual
beneficial effects among OA patients in terms of symptomatic
and functional improvement along with pain relief
thereby contributing to overall efficacy. It is interesting to
note that the onset of beneficial effect of NR-INF-02, an
herbal product was observed within 1 month. While it is
difficult to justify the same, it may be attributed to the
physicochemical properties of improved extract of polysaccharides
contributing to enhanced potency and therefore
pharmacological activity of this investigational product